Galapagos NV
OTC:GLPGF

Watchlist Manager
Galapagos NV Logo
Galapagos NV
OTC:GLPGF
Watchlist
Price: 31.68 USD Market Closed
Market Cap: 2.1B USD

Net Margin

-152%
Current
Declining
by 135.6%
vs 3-y average of -16.4%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-152%
=
Net Income
€-436.3m
/
Revenue
€286.9m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-152%
=
Net Income
$-436.3m
/
Revenue
€286.9m

Peer Comparison

Country Company Market Cap Net
Margin
BE
Galapagos NV
AEX:GLPG
1.9B EUR
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
386.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.2B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
163.5B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.6B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.5B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.4B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.7B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
48.4B USD
Loading...

Market Distribution

Lower than 95% of companies in Belgium
Percentile
5th
Based on 487 companies
5th percentile
-152%
Low
-13 700% — 1.5%
Typical Range
1.5% — 14.7%
High
14.7% — 97 950%
Distribution Statistics
Belgium
Min -13 700%
30th Percentile 1.5%
Median 7.4%
70th Percentile 14.7%
Max 97 950%

Galapagos NV
Glance View

Market Cap
2.1B USD
Industry
Biotechnology

Founded in 1999, Galapagos NV emerged from the rich scientific collaboration between the Netherlands and Belgium, initially as a joint venture between the Dutch company Crucell and the Flemish biotech company Tibotec. In its early years, Galapagos carved a niche for itself by focusing on the discovery of novel targets leading to the development of human proteins for medicines. Through its proprietary technological platforms, Galapagos identifies and validates these targets, setting the stage for developing small molecules that inhibit these specific proteins. This unique approach positions the company at the forefront of innovative drug discovery, primarily targeting inflammatory diseases, fibrosis, and other conditions where there is a significant unmet medical need. Revenue for Galapagos is generated through several streams, most notably from strategic partnership deals and potential milestone payments in the biotech sector. The heart of its business model lies in deep collaborations with major pharmaceutical companies like Gilead Sciences, which bolster its financial stability and provide mutual benefits in drug development ventures. Additionally, Galapagos advances its proprietary drug candidates in clinical trials, aiming to bring them to market and secure approval from regulatory bodies. By successfully moving these candidates through clinical development phases, it stands to secure substantial future revenue from both commercialization and licensing deals. With its innovative science-focused strategy, Galapagos continues to propel forward, endeavoring to transform scientific insights into tangible therapeutic advancements.

GLPGF Intrinsic Value
28.86 USD
Overvaluation 9%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-152%
=
Net Income
€-436.3m
/
Revenue
€286.9m
What is Galapagos NV's current Net Margin?

The current Net Margin for Galapagos NV is -152%, which is below its 3-year median of -16.4%.

How has Net Margin changed over time?

Over the last 3 years, Galapagos NV’s Net Margin has decreased from 0.9% to -152%. During this period, it reached a low of -152% on Sep 30, 2025 and a high of 88.3% on Dec 31, 2023.

Back to Top